Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Veterinary Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ZTS
- CUSIP: 98978V10
- Web: www.zoetis.com
Capitalization:- Market Cap: $30.99873 billion
- Outstanding Shares: 490,796,000
Average Prices:- 50 Day Moving Avg: $62.65
- 200 Day Moving Avg: $57.14
- 52 Week Range: $46.86 - $63.85
P/E:- Trailing P/E Ratio: 36.72
- Foreward P/E Ratio: 23.62
- P/E Growth: 2.10
Sales & Book Value:- Annual Revenue: $4.96 billion
- Price / Sales: 6.26
- Book Value: $3.28 per share
- Price / Book: 19.30
Dividend:- Annual Dividend: $0.42
- Dividend Yield: 0.7%
Profitability:- EBIDTA: $1.71 billion
- Net Margins: 17.25%
- Return on Equity: 65.35%
- Return on Assets: 13.06%
Debt:- Debt-to-Equity Ratio: 2.27%
- Current Ratio: 1.96%
- Quick Ratio: 1.07%
Misc:- Average Volume: 2.79 million shs.
- Beta: 1.03
- Short Ratio: 3.82
Frequently Asked Questions for Zoetis (NYSE:ZTS)
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Friday, May 12th. Investors of record on Thursday, June 15th will be paid a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date is Tuesday, June 13th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, May, 4th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.05. The company earned $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. Zoetis's revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 EPS. View Zoetis' Earnings History.
When will Zoetis make its next earnings announcement?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.26-2.36 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.32. The company issued revenue guidance of $5.10-5.225 billion, compared to the consensus revenue estimate of $5.17 billion.
Where is Zoetis' stock going? Where will Zoetis' stock price be in 2017?
18 equities research analysts have issued 12 month price targets for Zoetis' stock. Their forecasts range from $35.00 to $77.00. On average, they anticipate Zoetis' share price to reach $63.06 in the next year. View Analyst Ratings for Zoetis.
What are analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. According to Zacks Investment Research, "Zoetis’ growth in revenues is being driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. Shares of Zoetis have outperformed the industry in 2017 so far. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly among others. " (7/4/2017)
- 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Shire PLC (SHPG), Fresenius SE (FSNUY), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Vertex Pharmaceuticals Incorporated (VRTX), Boston Scientific Corporation (BSX), Express Scripts Holding Company (ESRX), McKesson Corporation (MCK), Intuitive Surgical (ISRG), Baxter International (BAX), Humana (HUM), Teva Pharmaceutical Industries Limited (TEVA) and HCA Holdings (HCA).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Juan Ramon Alaix, Chief Executive Officer, Director
- Glenn David, Chief Financial Officer, Executive Vice President
- Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
- Andrew Fenton, Executive Vice President, Chief Information Officer
- Heidi C. Chen, Executive Vice President, General Counsel, Corporate Secretary
- Alejandro Bernal, Executive Vice President, Group President - Strategy, Commercial and Business Development
- Catherine A. Knupp, Executive Vice President, President - Research and Development
- Clinton A. Lewis Jr., Executive Vice President, President - International Operations
- Kristin C. Peck, Executive Vice President, President - U.S. Operations
- Roman Trawicki, Executive Vice President, President of Global Manufacturing and Supply
Who owns Zoetis stock?
Zoetis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Treasurer State of Michigan (0.32%), AMF Pensionsforsakring AB (0.20%), Atalanta Sosnoff Capital LLC (0.15%), AMI Asset Management Corp (0.13%), Vontobel Asset Management Inc. (0.12%) and Bank of Montreal Can (0.11%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.
Who sold Zoetis stock? Who is selling Zoetis stock?
Zoetis' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Atalanta Sosnoff Capital LLC, Boussard & Gavaudan Investment Management LLP, Copeland Capital Management LLC, Quantitative Systematic Strategies LLC, AMI Asset Management Corp, Exxonmobil Investment Management Inc. TX and Daiwa SB Investments Ltd.. Company insiders that have sold Zoetis stock in the last year include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.
Who bought Zoetis stock? Who is buying Zoetis stock?
Zoetis' stock was acquired by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, State Treasurer State of Michigan, Hermes Investment Management Ltd., Mn Services Vermogensbeheer B.V., Gladstone Capital Management LLP, US Bancorp DE, OLD National Bancorp IN and Bank of Montreal Can. View Insider Buying and Selling for Zoetis.
How do I buy Zoetis stock?
Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of Zoetis stock can currently be purchased for approximately $63.29.
MarketBeat Community Rating for Zoetis (NYSE ZTS)MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zoetis (NYSE:ZTS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $63.06 (0.37% downside) |
Analysts' Ratings History for Zoetis (NYSE:ZTS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/21/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $65.00 | Low |  |
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $62.00 -> $65.00 | Low | |
| 7/17/2017 | Cowen and Company | Set Price Target | Buy | $70.00 | Low | |
| 6/20/2017 | Hilliard Lyons | Initiated Coverage | Buy | $77.00 | Low | |
| 6/16/2017 | Cantor Fitzgerald | Initiated Coverage | Overweight -> Overweight | $75.00 | Low | |
| 6/13/2017 | BMO Capital Markets | Downgrade | Outperform -> Market Perform | $64.00 -> $65.00 | Low | |
| 5/30/2017 | Argus | Reiterated Rating | Buy | $60.00 -> $69.00 | Low | |
| 5/26/2017 | CL King | Initiated Coverage | Buy -> Buy | $71.00 | Low | |
| 5/24/2017 | Credit Suisse Group | Boost Price Target | Outperform | $61.00 -> $67.00 | Low | |
| 5/9/2017 | Jefferies Group LLC | Boost Price Target | Buy | $65.00 -> $70.00 | Low | |
| 3/15/2017 | Craig Hallum | Initiated Coverage | Buy | $65.00 | Low | |
| 2/16/2017 | Guggenheim | Boost Price Target | Buy | $60.00 -> $65.00 | N/A | |
| 2/16/2017 | Off Wall Street | Reiterated Rating | Strong Sell | $35.00 | N/A | |
| 12/15/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $61.00 | N/A | |
| 11/3/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $53.00 | N/A | |
| 9/29/2016 | Bank of America Corporation | Initiated Coverage | Buy | $60.00 | N/A | |
| 8/4/2016 | Citigroup Inc. | Boost Price Target | Neutral | $50.00 -> $53.00 | N/A | |
| 8/4/2016 | Barclays PLC | Boost Price Target | Equal Weight | $45.00 -> $49.00 | N/A | |
| 5/6/2016 | Goldman Sachs Group, Inc. (The) | Downgrade | Neutral -> Sell | $46.00 -> $48.00 | N/A | |
| 1/8/2016 | Cleveland Research | Initiated Coverage | Buy | | N/A | |
| 8/6/2015 | William Blair | Upgrade | Market Perform -> Outperform | | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Zoetis (NYSE:ZTS)Earnings History by Quarter for Zoetis (NYSE ZTS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | | $0.53 | | | | | N/A | |
| 5/4/2017 | Q1 2017 | $0.48 | $0.53 | $1.20 billion | $1.23 billion | View | Listen | |
| 2/16/2017 | Q416 | $0.45 | $0.47 | $1.28 billion | $1.30 billion | View | N/A | |
| 11/2/2016 | Q316 | $0.46 | $0.52 | $1.22 billion | $1.20 billion | View | N/A | |
| 8/3/2016 | Q216 | $0.44 | $0.49 | $1.17 billion | $1.20 billion | View | N/A | |
| 5/4/2016 | Q116 | $0.41 | $0.48 | $1.10 billion | $1.20 billion | View | N/A | |
| 2/16/2016 | Q415 | $0.39 | $0.43 | $1.25 billion | $1.30 billion | View | Listen | |
| 11/3/2015 | Q315 | $0.40 | $0.50 | $1.18 billion | $1.20 billion | View | N/A | |
| 8/4/2015 | Q215 | $0.38 | $0.43 | $1.12 billion | $1.20 billion | View | N/A | |
| 5/5/2015 | Q115 | $0.37 | $0.41 | $1.11 billion | $1.10 billion | View | N/A | |
| 2/11/2015 | Q414 | $0.36 | $0.40 | $1.27 billion | $1.30 billion | View | N/A | |
| 11/4/2014 | Q314 | $0.37 | $0.41 | $1.16 billion | $1.20 billion | View | N/A | |
| 5/6/2014 | Q114 | $0.37 | $0.38 | $1.13 billion | $1.10 billion | View | N/A | |
| 2/11/2014 | Q413 | $0.34 | $0.36 | $1.21 billion | $1.25 billion | View | N/A | |
| 11/5/2013 | Q313 | $0.34 | $0.34 | $1.07 billion | $1.10 billion | View | N/A | |
| 8/6/2013 | Q2 2013 | $0.36 | $0.36 | $1.13 billion | $1.11 billion | View | N/A | |
| 4/30/2013 | Q1 2013 | $0.27 | $0.36 | $1.24 billion | $1.09 billion | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zoetis (NYSE:ZTS)2017 EPS Consensus Estimate: $2.25
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.47 | $0.49 | $0.48 |
| Q2 2017 | 1 | $0.50 | $0.50 | $0.50 |
| Q3 2017 | 1 | $0.62 | $0.62 | $0.62 |
| Q4 2017 | 1 | $0.65 | $0.65 | $0.65 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Zoetis (NYSE:ZTS)| Next Dividend: | 9/1/2017 |
| Annual Dividend: | $0.42 |
| Dividend Yield: | 0.66% |
| Dividend Growth: | 24.90% (3 Year Average) |
| Payout Ratio: | 24.42% (Trailing 12 Months of Earnings)
18.03% (Based on This Year's Estimates)
15.67% (Based on Next Year's Estimates)
|
| Track Record: | 3 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Zoetis (NYSE ZTS)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/12/2017 | quarterly | $0.11 | 0.7% | 6/13/2017 | 6/15/2017 | 9/1/2017 |
| 2/15/2017 | quarterly | $0.11 | 0.76% | 4/4/2017 | 4/6/2017 | 6/1/2017 |
| 12/6/2016 | quarterly | $0.11 | 0.82% | 1/18/2017 | 1/20/2017 | 3/1/2017 |
| 10/7/2016 | quarterly | $0.10 | 0.73% | 11/1/2016 | 11/3/2016 | 12/1/2016 |
| 5/13/2016 | quarterly | $0.10 | 0.82% | 6/28/2016 | 6/30/2016 | 8/30/2016 |
| 2/22/2016 | quarterly | $0.10 | 0.89% | 4/5/2016 | 4/7/2016 | 6/1/2016 |
| 12/17/2015 | quarterly | $0.10 | 0.81% | 1/19/2016 | 1/21/2016 | 3/1/2016 |
| 10/2/2015 | quarterly | $0.08 | 0.77% | 11/3/2015 | 11/5/2015 | 12/1/2015 |
| 7/22/2015 | quarterly | $0.08 | 0.66% | 8/11/2015 | 8/13/2015 | 9/1/2015 |
| 3/2/2015 | quarterly | $0.08 | 0.7% | 4/7/2015 | 4/9/2015 | 6/2/2015 |
| 12/18/2014 | quarterly | $0.08 | 0.77% | 1/20/2015 | 1/22/2015 | 3/3/2015 |
| 10/2/2014 | quarterly | $0.07 | 0.76% | 11/3/2014 | 11/5/2014 | 12/2/2014 |
| 7/31/2014 | quarterly | $0.07 | 0.88% | 8/18/2014 | 8/20/2014 | 9/2/2014 |
| 3/26/2014 | quarterly | $0.07 | 0.98% | 4/23/2014 | 4/27/2014 | 6/2/2014 |
| 12/19/2013 | quarterly | $0.07 | 0.89% | 1/28/2014 | 1/30/2014 | 3/4/2014 |
| 9/12/2013 | quarterly | $0.07 | 0.84% | 10/30/2013 | 11/1/2013 | 12/2/2013 |
| 6/20/2013 | quarterly | $0.07 | | | 8/1/2013 | 9/2/2013 |
| 3/29/2013 | special | $0.07 | | 4/29/2013 | 5/1/2013 | 6/6/2013 |
| 3/28/2013 | quarterly | $0.07 | | | 5/1/2013 | 6/6/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Zoetis (NYSE:ZTS)Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 95.20%
Insider Trades by Quarter for Zoetis (NYSE:ZTS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/12/2017 | Catherine A Knupp | Insider | Sell | 5,785 | $60.16 | $348,025.60 | |
| 11/22/2016 | Kristin C Peck | Insider | Sell | 10,092 | $49.55 | $500,058.60 | |
| 11/8/2016 | Roxanne Lagano | Insider | Sell | 9,797 | $50.43 | $494,062.71 | |
| 9/6/2016 | Michael B Mccallister | Director | Buy | 2,000 | $51.34 | $102,680.00 | |
| 9/2/2016 | Andrew Fenton | Insider | Sell | 13,870 | $51.25 | $710,837.50 | |
| 9/1/2016 | Heidi C Chen | Insider | Sell | 32,097 | $50.98 | $1,636,305.06 | |
| 5/9/2016 | Pershing Square Capital Manage | Director | Sell | 16,850,000 | $46.55 | $784,367,500.00 | |
| 8/8/2013 | Michael Mccallister | Director | Buy | 7,000 | $31.35 | $219,450.00 | |
| 2/6/2013 | Frank A Damelio | Director | Buy | 5,000 | $26.00 | $130,000.00 | |
| 2/6/2013 | Sandra J Beaty | EVP | Buy | 2,000 | $26.00 | $52,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zoetis (NYSE:ZTS)
Latest Headlines for Zoetis (NYSE:ZTS)
| Source: |
|
| Date | Headline |
|---|
 | Zoetis (NYSE:ZTS) & Aratana Therapeutics (PETX) Financial Review
www.americanbankingnews.com - July 24 at 10:19 PM |
| Zoetis Inc. (NYSE:ZTS) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 21 at 4:52 PM |
| Zoetis Inc. (ZTS) Price Target Increased to $65.00 by Analysts at Deutsche Bank AG
www.americanbankingnews.com - July 17 at 5:58 PM |
 | ETFs with exposure to Zoetis, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 8:39 PM |
 | Kindred Biosciences: Up 100% YTD With Even Greater Potential In H2
seekingalpha.com - July 13 at 11:35 AM |
| Zoetis Inc. (NYSE:ZTS) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - July 12 at 10:40 PM |
| Performance of Zoetis Stock in 2Q17
finance.yahoo.com - July 11 at 9:56 AM |
| Zoetis Inc. (ZTS) Expected to Post FY2017 Earnings of $2.26 Per Share
www.americanbankingnews.com - July 6 at 8:00 AM |
| Zoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 5:22 PM |
| Zacks Investment Research Lowers Zoetis Inc. (NYSE:ZTS) to Hold
www.americanbankingnews.com - July 4 at 1:04 PM |
| Critical Review: Aratana Therapeutics (PETX) versus Zoetis (ZTS)
www.americanbankingnews.com - July 2 at 4:34 PM |
| Zoetis to Host Webcast and Conference Call on Second Quarter 2017 Financial Results
finance.yahoo.com - July 1 at 9:23 AM |
| ETFs with exposure to Zoetis, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 9:23 AM |
| Phibro Animal Health Corporation (PAHC) vs. Zoetis (ZTS) Critical Review
www.americanbankingnews.com - June 29 at 10:49 AM |
| Cramer's lightning round: Don't go down the food chain in this space
finance.yahoo.com - June 22 at 7:59 PM |
 | Hilliard Lyons Reinstates Zoetis Inc. (ZTS) at Buy, "A Top Operator in an Industry with Solid Secular Growth" - StreetInsider.com
www.streetinsider.com - June 22 at 2:57 PM |
| Critical Review: Zoetis (ZTS) and Phibro Animal Health Corporation (PAHC)
www.americanbankingnews.com - June 21 at 10:20 AM |
| Zoetis Inc. (ZTS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 20 at 4:10 PM |
| ETFs with exposure to Zoetis, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 3:48 PM |
| Zoetis, Inc. :ZTS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 20 at 9:29 AM |
| Zoetis Inc. (ZTS) Now Covered by Analysts at Hilliard Lyons
www.americanbankingnews.com - June 20 at 9:21 AM |
| $1.25 Billion in Sales Expected for Zoetis Inc. (ZTS) This Quarter
www.americanbankingnews.com - June 18 at 8:14 AM |
| Zoetis Inc. (ZTS) Now Covered by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 17 at 10:28 AM |
| Zoetis Inc. (ZTS) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - June 16 at 10:22 PM |
| UPDATE: Cantor Fitzgerald Starts Zoetis Inc. (ZTS) at Overweight, Sees Upside To EPS Estimates From M&A Among ... - StreetInsider.com
www.streetinsider.com - June 16 at 2:24 AM |
| Zoetis, Inc. : ZTS-US: Dividend Analysis : June 15th, 2017 (record date) : By the numbers : June 15, 2017
finance.yahoo.com - June 15 at 4:19 PM |
| BMO Capital Downgrades Zoetis Inc. (ZTS) to Market Perform
www.streetinsider.com - June 14 at 9:34 PM |
| Looking For A Better Entry Point, BMO Downgrades Zoetis Shares
finance.yahoo.com - June 14 at 2:32 AM |
| Zoetis Inc. (ZTS) Downgraded by BMO Capital Markets to "Market Perform"
www.americanbankingnews.com - June 13 at 8:28 AM |
| Zoetis Stock Is Sizzling Hot -- Here's What Could Make It Cool Down
finance.yahoo.com - June 11 at 8:34 AM |
 | Zoetis Stock Is Sizzling Hot -- Here's What Could Make It Cool Down
www.fool.com - June 11 at 7:32 AM |
| Zoetis Inc (ZTS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 4:32 PM |
| Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 3:12 AM |
| Zoetis Just Hit an All-Time High: Here's Why the Stock Should Go Higher
www.fool.com - June 3 at 12:49 PM |
| Zoetis to Participate in the William Blair Growth Stock Conference
finance.yahoo.com - June 2 at 8:19 AM |
| Argus Reiterates Buy Rating for Zoetis Inc (ZTS)
www.americanbankingnews.com - May 30 at 1:51 PM |
 | Zoetis Reaches Analyst Target Price
www.nasdaq.com - May 26 at 9:11 AM |
| Zoetis to Participate in the Stifel 2017 Dental and Veterinary Conference
finance.yahoo.com - May 26 at 9:11 AM |
| Zoetis Inc (ZTS) Research Coverage Started at CL King
www.americanbankingnews.com - May 26 at 9:04 AM |
| Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
finance.yahoo.com - May 25 at 8:13 AM |
| Credit Suisse Group AG Reiterates Outperform Rating for Zoetis Inc (ZTS)
www.americanbankingnews.com - May 24 at 9:34 PM |
| Zoetis (ZTS): Raising PT - Credit Suisse - StreetInsider.com
www.streetinsider.com - May 24 at 8:00 AM |
| Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
finance.yahoo.com - May 23 at 8:14 PM |
| Can These 3 High-Flying Healthcare Stocks Reach the Clouds?
www.fool.com - May 23 at 3:22 PM |
| 3 Top Animal-Health Companies to Buy in 2017
www.fool.com - May 21 at 3:20 PM |
| What’s Really Driving Zoetis’s Margins in 2017?
finance.yahoo.com - May 19 at 1:57 PM |
| Inside Zoetis’s Growth Strategy in 2017
finance.yahoo.com - May 19 at 1:57 PM |
| Behind Zoetis’s Multi-Pronged Strategy to Strengthen Its Product Portfolio
finance.yahoo.com - May 18 at 8:15 AM |
| Inside Zoetis’s Key Revenue Drivers
finance.yahoo.com - May 17 at 11:42 PM |
| Why Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues
finance.yahoo.com - May 17 at 11:42 PM |
Zoetis (ZTS) Chart for Tuesday, July, 25, 2017
